Disufenton sodium (Cerovive, OKN-007, NXY-059, HPN-07)[1] is a free radical trapping
nitrone-based
antioxidant compound that has been under development for several medical conditions.[2][3]
Chemistry
Disufenton sodium is the disulfonyl derivative of the neuroprotective nitrone
spin trapphenylbutylnitrone or "PBN". PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.
Research
Disufenton sodium was under development at the drug company
AstraZeneca. A 2005 phase-3 clinical trial[4][5] called "SAINT-1" reported some efficacy in the acute treatment of
ischemia injury due to
stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance".[4] AstraZeneca then terminated the development programme.[6]
^Battiste JD, Ikeguchi A, Woo S, Sharan S, Zhao YD, Cohoon A, et al. (May 20, 2020). "Phase Ib clinical trial of OKN-007 in recurrent malignant glioma". Journal of Clinical Oncology. 38 (15_suppl). American Society of Clinical Oncology (ASCO): 2538.
doi:
10.1200/jco.2020.38.15_suppl.2538.
ISSN0732-183X.
S2CID219772612.
Fong JJ, Rhoney DH (March 2006). "NXY-059: review of neuroprotective potential for acute stroke". The Annals of Pharmacotherapy. 40 (3): 461–471.
doi:
10.1345/aph.1E636.
PMID16507608.
S2CID38016035.
Warner DS, Sheng H, Batinić-Haberle I (August 2004). "Oxidants, antioxidants and the ischemic brain". The Journal of Experimental Biology. 207 (Pt 18): 3221–3231.
doi:
10.1242/jeb.01022.
PMID15299043.
S2CID15392635.